Goldman Sachs – Pharma Versus Biotech ValuationRupert Hargreaves
Goldman Sachs put out a new research report this week which asks the question “pharma versus biotech: which is cheaper?”
Since the start of the great healthcare bull run, which began during 2011, healthcare earnings multiples have risen from 12 times earnings, to 17.6 times earnings and the sector now trades at a slight premium to the S&P 500. The S&P 500 trades at a P/E of 17 according to Goldman’s data.
But not all healthcare sectors are created equal . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible